Avid Bioservices Inc (CDMO)

[tech0200]

Any drug can be sold on the slightest chance that it might be approved. The value of the drug is determined by what phase the drug is in and the market for its indication. Drugs in the pre-clinical stage have been sold for millions, drug in phase I for tens of millions, drugs in phase II for billions. Bavi made it to phase III and it could have easily fetched 10+ billions based on the breast cancer market alone. Add to that all of the other potential cancers that it could have been approved for.

It could have made other drugs more effective, safer, and more profitable. Add to that the exosomes and Betabodies. And the value would have gone even higher.

You stated in the past that Bavi was never worth anything. A drug that makes in phase II for a cancer like breast cancer can easily be sold for billions. When Bavi made it to phase III the price went even higher. The problem is the BOD decided to go at it alone. They could have sold or partnered if they chose to do that and it would have been a much different story.